He X, Lloyd E, Cooper S, Li L, Chauhan D, Juliao P, Quasny H, Bao C. Healthcare costs and utilization for patients with systemic lupus erythematosus in China: a national claims database study. Value in Health Regional Issues. 2023 Sep;37:88-96. doi: 10.1016/j.vhri.2023.03.007
Jiang S, Varghese D, Appukkuttan S, Corman S, Kebede N, Gnanasakthy K, Macahilig C, Waldeck R, Hussain A. Real-world incidence and management of adverse events (AE) in patients with non-metastatic castrate-resistant prostate cancer receiving apalutamide or enzalutamide. Poster presented at the 2020 Virtual ISPOR Asia Pacific Conference; September 10, 2020. [abstract] Value in Health Regional Issues. 2020 Sep 1; 22(Supplement):S4-5.
Basarir H, Brockbank J, Knight C, Wolowacz S. The inclusion of the utility values for carers and family members in HTAs: a case study of recent NICE appraisals in the UK. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 22, 2019. New Orleans, LA. [abstract] Value in Health Regional Issues. 2019 May; 22(Suppl 2):S330.
Roosli M, Foraster M, Feychting M, Huss A. ASPHER's European list of core competences for the public health professional. Scand J Public Health. 2018 Nov 13;46(23 Suppl):1-52. doi: 10.1177/1403494818797072
Winnette R, Zárate V, Machnicki G, Demuro-Mercon C, Gawlicki M, Gnanasakthy A. Patient-reported outcomes in Latin America: implementation in research and role in emerging HTA systems. Value in Health Regional Issues. 2015 Dec;8:49-55. doi: 10.1016/j.vhri.2015.03.008
Hogue S, Hollis K, Silvia S, Wooddell M. The EpiPen4Schools® survey: staff training and use of epinephrine auto-injectors for the treatment of anaphylaxis in large US school districts. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. [abstract] Value in Health Regional Issues. 2015 Nov; 18(7):A505. doi: 10.1016/j.jval.2015.09.1441
Martin-Richard M, Gallego R, Pericay C, Garcia Foncillas JG, Queralt B, Casado E, Barriuso J, Iranzo V, Juez I, Visa L, Saigi E, Barnadas A, Garcia-Albeniz X, Maurel J. Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study. Invest New Drugs. 2013 Dec;31(6):1573-9.
Selimovic N, Rundqvist B, Kjork E, Viriden J, Twiss J, McKenna SP. Adaptation and validation of the cambridge pulmonary hypertension outcome review for Sweden. Scand J Public Health. 2012 Dec;40(8):777-83. doi: 10.1177/1403494812464445
Brown TM, Horblyuk RV, Grotzinger KM, Matzdorff AC, Pashos CL. Patient-reported treatment burden of chronic immune thrombocytopenia therapies. BMC Blood Disord. 2012 Mar 1;12(1):2.